Percentage of ownership in a legal entity with a potential role in the management.

No definition available.

Name:	grce_BeneficialOwnerPercentageOfCommonStockOutstandingPriorToOfferings
Namespace Prefix:	grce_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Ratio applied to the common share and each pre-funded warrant issued in the offering.

+ References

No definition available.

+ Details

Name:	grce_CommonSharesAndPreFundedWarrantIssuedRatio
Namespace Prefix:	grce_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement, net of fees and expenses.

+ References

No definition available.

+ Details

Name:	grce_ProceedsFromIssuanceOfPrivatePlacementNet
Namespace Prefix:	grce_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Class of warrant or right, issue price.

+ References

No definition available.

+ Details

Name:	grce_WarrantIssuePrice
Namespace Prefix:	grce_
Data Type:	dtr:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Face amount or stated value per share of common stock.

+ References

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:	us-gaap_CommonStockSharesAuthorized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=grce_PreFundedWarrants2025Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=grce_CommonWarrantAndPreFundedWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=grce_CommonWarrant2025Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=grce_PreFundedWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=grce_CommonWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=grce_PrivatePlacement2025Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=grce_ADAR1PartnersLPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=grce_AIGHInvestmentPartnersLPMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=grce_CommonWarrantShareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=grce_PrivatePlacement2023Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Stockholders' equity - 2025 Private Placement, 2023 Private Placement (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Feb. 11, 2025 USD ($) $ / shares shares	Sep. 25, 2023 USD ($) $ / shares shares	Mar. 31, 2025 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($)
Shareholders Equity [Abstract]
Common stock, shares authorized (in shares)			100,000,000	100,000,000
Common stock, par value (in Dollars per share) \| $ / shares			$ 0.0001	$ 0.0001
Warrant exercise price (in Dollars per share) \| $ / shares			$ 0.45	$ 1.72
Net proceeds from private placement (in Dollars) \| $	$ 13,705
Term of warrants			5 years
Derivative warrant liabilities (in Dollars) \| $			$ 1,141	$ 4,359	$ 0
SS Pharma LLC [Member]
Shareholders Equity [Abstract]
Derivative warrant liabilities (in Dollars) \| $			$ 952	$ 1,453
2025 Pre-Funded Warrants [Member]
Shareholders Equity [Abstract]
Warrant exercise price (in Dollars per share) \| $ / shares			$ 0.0001
Common Warrant and Pre-Funded Warrant [Member]
Shareholders Equity [Abstract]
Number of shares of common stock that can be purchased with warrants (in shares)		4,643,244
Term of warrants			5 years
2025 Common Warrant [Member]
Shareholders Equity [Abstract]
Warrant exercise price (in Dollars per share) \| $ / shares			$ 3.395
Pre-funded Warrants [Member]
Shareholders Equity [Abstract]
Warrant exercise price (in Dollars per share) \| $ / shares			0.0001
Common Warrants [Member]
Shareholders Equity [Abstract]
Warrant exercise price (in Dollars per share) \| $ / shares			$ 3.003
2025 Private Placement [Member]
Shareholders Equity [Abstract]
Common stock, shares authorized (in shares)	3,252,132
Purchase price per common share (in Dollars per share) \| $ / shares	$ 3.395
Common stock, par value (in Dollars per share) \| $ / shares	$ 0.0001
Net proceeds from private placement (in Dollars) \| $	$ 13,705
2025 Private Placement [Member] \| SS Pharma LLC [Member]
Shareholders Equity [Abstract]
Net proceeds from private placement (in Dollars) \| $	$ 5,694
2025 Private Placement [Member] \| 2025 Pre-Funded Warrants [Member]
Shareholders Equity [Abstract]
Number of shares of common stock that can be purchased with warrants (in shares)	1,166,160
Common stock, par value (in Dollars per share) \| $ / shares	$ 0.0001
Number of shares issued upon exercise of each warrant (in shares)	1
Warrant exercise price (in Dollars per share) \| $ / shares	$ 3.3949
2025 Private Placement [Member] \| Common Warrant and Pre-Funded Warrant [Member]
Shareholders Equity [Abstract]
Number of shares of common stock that can be purchased with warrants (in shares)	4,418,292
2025 Private Placement [Member] \| 2025 Common Warrant [Member]
Shareholders Equity [Abstract]
Class of warrant or right, issue price (in Dollars per share) \| $ / shares	$ 0.125
2025 Private Placement [Member] \| Pre-funded Warrants [Member]
Shareholders Equity [Abstract]
Number of shares of common stock that can be purchased with warrants (in shares)			24,742
2025 Private Placement [Member] \| Minimum [Member] \| ADAR1 Partners, LP [Member]
Shareholders Equity [Abstract]
Beneficial owner percentage	5.00%
2025 Private Placement [Member] \| Minimum [Member] \| AIGH Investment Partners, LP [Member]
Shareholders Equity [Abstract]
Beneficial owner percentage	5.00%
2025 Private Placement [Member] \| Minimum [Member] \| SS Pharma LLC [Member]
Shareholders Equity [Abstract]
Beneficial owner percentage	5.00%
2025 Private Placement [Member] \| Common Warrant Share [Member]
Shareholders Equity [Abstract]
Warrant exercise price (in Dollars per share) \| $ / shares	$ 3.395
2025 Private Placement [Member] \| Common Warrant Share [Member] \| 2025 Common Warrant [Member]
Shareholders Equity [Abstract]
Number of shares issued upon exercise of each warrant (in shares)	1
2025 Private Placement [Member] \| Common Stock [Member]
Shareholders Equity [Abstract]
Warrants exercised into common stock (in shares)			24,742
2023 Private Placement [Member]
Shareholders Equity [Abstract]
Number of shares of common stock that can be purchased with warrants (in shares)				0
Warrant exercise price (in Dollars per share) \| $ / shares		$ 0.0001
Warrants exercised into common stock (in shares)		1,951,371
Common shares sold price per share (in Dollars per share) \| $ / shares		$ 1.848
Net proceeds from offering (in Dollars) \| $		$ 7,338
2023 Private Placement [Member] \| SS Pharma LLC [Member]
Shareholders Equity [Abstract]
Beneficial owner percentage		5.50%
Net proceeds from private placement (in Dollars) \| $		$ 2,500
2023 Private Placement [Member] \| Common Warrant and Pre-Funded Warrant [Member]
Shareholders Equity [Abstract]
Common shares and pre-funded warrant issued ratio		(0.625)
2023 Private Placement [Member] \| Pre-funded Warrants [Member]
Shareholders Equity [Abstract]
Number of shares of common stock that can be purchased with warrants (in shares)			1,041,851
Number of shares issued upon exercise of each warrant (in shares)		1
Warrant exercise price (in Dollars per share) \| $ / shares		$ 0.0001
2023 Private Placement [Member] \| Common Warrants [Member]
Shareholders Equity [Abstract]
Number of shares of common stock that can be purchased with warrants (in shares)		2,536,391
2023 Private Placement [Member] \| Maximum [Member] \| Pre-funded Warrants [Member]
Shareholders Equity [Abstract]
Number of shares of common stock that can be purchased with warrants (in shares)		2,106,853
2023 Private Placement [Member] \| Common Stock [Member]
Shareholders Equity [Abstract]
Warrant exercise price (in Dollars per share) \| $ / shares		$ 3.003
Warrants exercised into common stock (in shares)			1,041,828
2023 Private Placement [Member] \| Common Stock [Member] \| Common Warrants [Member]
Shareholders Equity [Abstract]
Number of shares issued upon exercise of each warrant (in shares)		1